NeoGenomics (NEO) TD Cowen 45th Annual Healthcare Conference summary

Leadership transition and strategic direction

• Incoming CEO Tony Zook emphasized continuity in strategy, focusing on customer excellence, financial discipline, and lab efficiencies, while evolving toward greater R&D and product innovation.

• The outgoing CEO highlighted successful turnaround efforts, including rebuilding the leadership team, achieving nine consecutive quarters of double-digit growth, and improving adjusted EBITDA from a $48 million loss to a $40 million gain.

• The CEO transition was described as well-planned, with Tony Zook having been involved in board-level strategy and long-range planning, ensuring alignment and stability.

• The management team expressed confidence in the depth and stability of leadership, with strong succession planning and upskilling at multiple organizational levels.

• The team addressed investor concerns about the transition, emphasizing the business's solid foundation and bright outlook.

Business performance and outlook

• Clinical revenue grew 15% in both Q4 and the full year, with continued momentum expected in 2025, supported by a 30% increase in sales force and new product launches.

• Non-clinical (pharma) revenue faced headwinds due to delayed pharma spending, but bookings have materially increased, with growth expected to return in 2025 and accelerate thereafter.

• The company maintained its guidance for 11-13% revenue growth in 2025, driven by clinical expansion, new products, and stabilization in pharma.

• Long-term revenue growth guidance was raised to 12-13%, underpinned by robust NGS growth, expanded sales resources, and operational efficiencies.

• Margin expansion is expected through operating leverage, higher-value tests, pricing improvements, and efficiency initiatives like LIMS and automation.

Product innovation and market positioning

• The PanTracer liquid biopsy test is positioned to fill a key portfolio gap, targeting community oncologists and expected to drive accelerated NGS growth.

• The Neo Comprehensive solid tumor test, launched in 2023, now represents 30% of clinical revenues and is projected to grow 25% in 2024.

• The company is leveraging its broad test portfolio and customer service to consolidate vendor relationships and reduce administrative burden for clients.

• Advanced diagnostics and pharma offerings have been realigned to therapy types and standardized workflows, with a new Hunter Pharma sales model to expand customer reach.

• MRD (minimal residual disease) development is advancing, with 1.1 nearing CLIA validation and a court case in October, while next-generation MRD remains a focus for future growth.